Epidiolex
NICE refuses GW Pharma’s cannabis-based Epidyolex for treatment-resistant epilepsy
August 27, 2019Manufacturing and Production, Sales and Marketing Epidiolex, Epidyolex, GW Pharma, NICE, cannabidiol, cannabis, pharma
UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS …
GW Pharma’s cannabis-based Epidyolex edges closer to EU approval with positive CHMP opinion in epilepsy
July 26, 2019Medical Communications, Sales and Marketing EMA, Epidiolex, Europe, GW Pharma, cannabis, epilepsy
UK-based biotech GW Pharmaceuticals has announced that its cannabidiol oral solution Epidyolex has secured recommendation from the European Medicines Agency’s …
GW Pharma’s Epidiolex scores in rare childhood onset epilepsy Phase 3 trial
May 7, 2019Manufacturing and Production, Sales and Marketing CBD, Epidiolex, GW Pharma, cannabidiol, cannabis, epilepsy, tsc
GW Pharma’s Epidiolex has shown positive Phase 3 trial results for the fifth time in a row, after meeting primary …
Australian firm Althea enters UK medicinal cannabis market
February 13, 2019Research and Development Epidiolex, GW Pharma, Medical marijuana, NHS, UK, cannabis
Melbourne-based medicinal cannabis company Althea has become one of the first companies to enter the UK market after the British …
GW Pharma’s Epidiolex becomes first cannabis-based medicine to be made available in United States
November 2, 2018Medical Communications Epidiolex, GW Pharma, Medical marijuana, cannabidiol, cannabis
GW Pharma’s Epidiolex has become the first plant-derived, cannabis-based medicine to be made available on prescription in all 50 US …
FDA advisory committee sets GW Pharma up for approval
April 20, 2018Medical Communications, Sales and Marketing Epidiolex, GW Pharma, biotech, drugs, pharma, pharmaceutical
After the FDA advisory committee unanimously recommended GW Pharma’s Epidiolex for approval, the chances of it not receiving the nod …
GW Pharma releases positive data on cannabidiol-based Phase III trial
September 28, 2016Research and Development Epidiolex, GW Pharmaceuticals, Marijuana, Medical marijuana, cannabis
GW Pharmaceuticals’ Epidiolex is designed to treat seizures in a rare form of epilepsy called Lennox-Gaustaut Syndrome. GW pharmaceuticals published …
GW Pharmaceuticals says Phase III trials for Epidiolex to treat rare epilepsy in children shows positive results
June 27, 2016Research and Development, Sales and Marketing Epidiolex, GW Pharmaceuticals, NDA, US FDA, drug trial, orphan drug
GW Pharmaceuticals (Nasdaq: GWPH) said late-stage trials for its Epidiolex (cannabidiol or CBD) to treat Lennox-Gastaut syndrome (LGS), a rare …
GW Pharma starts Phase III trials for Tuberous Sclerosis Complex drug
April 11, 2016Research and Development Epidiolex, GW Pharmaceuticals, Tuberous Sclerosis Complex, genetics, rare disease
GW Pharmaceuticals Plc (Nasdaq: GWPH) said it has started late-stage trials for its Epidiolex (cannabidiol or CBD) to treat seizures …
GW Pharma shares more than double after positive Phase III trials for epilepsy drug
March 15, 2016Manufacturing and Production, Research and Development Epidiolex, GW Pharma, US FDA, epilepsy in children, phase III
Shares in UK-based GW Pharmaceuticals (Nasdaq: GWPH) more than doubled on the Nasdaq Monday after the company announced positive results …
Late-stage failure for Otsuka and GW cancer pain drug
January 9, 2015Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …
Latest content
